Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Account Payables (2023 - 2025)

Monte Rosa Therapeutics' Change in Account Payables history spans 3 years, with the latest figure at -$10.6 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 179.74% year-over-year to -$10.6 million; the TTM value through Dec 2025 reached -$13.7 million, down 319.26%, while the annual FY2025 figure was -$13.7 million, 319.26% down from the prior year.
  • Change in Account Payables reached -$10.6 million in Q4 2025 per GLUE's latest filing, down from $8.9 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $13.3 million in Q4 2024 to a low of -$10.9 million in Q1 2025.
  • Average Change in Account Payables over 3 years is -$141500.0, with a median of -$348000.0 recorded in 2023.
  • Peak YoY movement for Change in Account Payables: crashed 1756.86% in 2024, then surged 473.11% in 2025.
  • A 3-year view of Change in Account Payables shows it stood at $5.8 million in 2023, then soared by 130.72% to $13.3 million in 2024, then plummeted by 179.74% to -$10.6 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Change in Account Payables are -$10.6 million (Q4 2025), $8.9 million (Q3 2025), and -$1.1 million (Q2 2025).